A detailed history of Gsa Capital Partners LLP transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 27,350 shares of XERS stock, worth $83,691. This represents 0.01% of its overall portfolio holdings.

Number of Shares
27,350
Previous 605,663 95.48%
Holding current value
$83,691
Previous $1.36 Million 94.28%
% of portfolio
0.01%
Previous 0.1%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$2.06 - $2.96 $1.19 Million - $1.71 Million
-578,313 Reduced 95.48%
27,350 $78,000
Q2 2024

Aug 15, 2024

BUY
$1.7 - $2.45 $1.01 Million - $1.46 Million
593,952 Added 5071.74%
605,663 $1.36 Million
Q1 2024

May 03, 2024

SELL
$2.04 - $3.22 $825,294 - $1.3 Million
-404,556 Reduced 97.19%
11,711 $25,000
Q4 2023

Feb 16, 2024

BUY
$1.47 - $2.36 $51,502 - $82,684
35,036 Added 9.19%
416,267 $978,000
Q3 2023

Nov 15, 2023

BUY
$1.8 - $2.69 $626,428 - $936,163
348,016 Added 1047.77%
381,231 $709,000
Q2 2023

Aug 14, 2023

SELL
$1.82 - $2.98 $514,714 - $842,773
-282,810 Reduced 89.49%
33,215 $87,000
Q1 2023

May 12, 2023

BUY
$1.03 - $1.63 $325,505 - $515,120
316,025 New
316,025 $515,000
Q3 2022

Nov 14, 2022

BUY
$1.37 - $1.93 $7,477 - $10,533
5,458 Added 12.23%
50,094 $78,000
Q2 2022

Aug 09, 2022

SELL
$1.48 - $2.64 $107,553 - $191,851
-72,671 Reduced 61.95%
44,636 $69,000
Q1 2022

May 11, 2022

BUY
$2.0 - $2.87 $12,070 - $17,320
6,035 Added 5.42%
117,307 $300,000
Q4 2021

Feb 14, 2022

BUY
$1.8 - $2.93 $200,289 - $326,026
111,272 New
111,272 $326,000

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $416M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.